PL2970191T3 - Pochodne pirydyny jako inhibitory kinazy przebudowanej podczas transfekcji (RET) - Google Patents

Pochodne pirydyny jako inhibitory kinazy przebudowanej podczas transfekcji (RET)

Info

Publication number
PL2970191T3
PL2970191T3 PL14713598T PL14713598T PL2970191T3 PL 2970191 T3 PL2970191 T3 PL 2970191T3 PL 14713598 T PL14713598 T PL 14713598T PL 14713598 T PL14713598 T PL 14713598T PL 2970191 T3 PL2970191 T3 PL 2970191T3
Authority
PL
Poland
Prior art keywords
remodeled
ret
transfected
kinase
inhibitors
Prior art date
Application number
PL14713598T
Other languages
English (en)
Polish (pl)
Inventor
Hilary Schenck Eidam
Michael P. Demartino
Zhen Gong
Amy Huiping Guan
Kaushik Raha
Chengde Wu
Haiying Yang
Haiyu Yu
Zhiliu Zhang
Mui Cheung
Original Assignee
Glaxosmithkline Intellectual Property Development Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Intellectual Property Development Limited filed Critical Glaxosmithkline Intellectual Property Development Limited
Publication of PL2970191T3 publication Critical patent/PL2970191T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/69Two or more oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL14713598T 2013-03-15 2014-03-14 Pochodne pirydyny jako inhibitory kinazy przebudowanej podczas transfekcji (RET) PL2970191T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2013072683 2013-03-15
CN2013090059 2013-12-20
CN2014072449 2014-02-24
EP14713598.2A EP2970191B1 (en) 2013-03-15 2014-03-14 Pyridine derivatives as rearranged during transfection (ret) kinase inhibitors

Publications (1)

Publication Number Publication Date
PL2970191T3 true PL2970191T3 (pl) 2017-07-31

Family

ID=50390154

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14713598T PL2970191T3 (pl) 2013-03-15 2014-03-14 Pochodne pirydyny jako inhibitory kinazy przebudowanej podczas transfekcji (RET)

Country Status (33)

Country Link
US (2) US9382238B2 (enExample)
EP (1) EP2970191B1 (enExample)
JP (1) JP2016516026A (enExample)
CN (1) CN105051027A (enExample)
AU (1) AU2014229233B2 (enExample)
BR (1) BR112015023618A2 (enExample)
CA (1) CA2905627A1 (enExample)
CL (1) CL2015002514A1 (enExample)
CR (1) CR20150490A (enExample)
CY (1) CY1118730T1 (enExample)
DK (1) DK2970191T3 (enExample)
DO (1) DOP2015000244A (enExample)
EA (1) EA029296B1 (enExample)
ES (1) ES2616655T3 (enExample)
HR (1) HRP20170363T1 (enExample)
HU (1) HUE033423T2 (enExample)
IL (1) IL241161A0 (enExample)
LT (1) LT2970191T (enExample)
ME (1) ME02664B (enExample)
MX (1) MX2015012286A (enExample)
NZ (1) NZ628388A (enExample)
PE (1) PE20151538A1 (enExample)
PH (1) PH12015502044A1 (enExample)
PL (1) PL2970191T3 (enExample)
PT (1) PT2970191T (enExample)
RS (1) RS55710B1 (enExample)
SG (1) SG11201506695UA (enExample)
SI (1) SI2970191T1 (enExample)
SM (1) SMT201700152T1 (enExample)
TW (1) TW201524958A (enExample)
UA (1) UA115264C2 (enExample)
UY (1) UY35465A (enExample)
WO (1) WO2014141187A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2735545C2 (ru) 2010-05-20 2020-11-03 Эррэй Биофарма Инк. Макроциклические соединения в качестве ингибиторов киназы trk
US20170283404A1 (en) * 2014-09-08 2017-10-05 Glaxosmithkline Intellectual Property Development Limited Crystalline forms of 2-(4-(4-ethoxy-6-oxo-1,6-dihydropyridin-3-yl)-2-fluorophenyl)-n-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)acetamide
RS58813B1 (sr) * 2014-09-10 2019-07-31 Glaxosmithkline Ip Dev Ltd Piridonski derivati korišćeni kao inhibitori kinaze reorganizovane tokom transfekcije (ret)
MX381233B (es) 2014-09-10 2025-03-12 Glaxosmithkline Ip Dev Ltd Nuevos compuestos como inhibidores de reorganizado durante la transfección (ret).
WO2016127074A1 (en) 2015-02-06 2016-08-11 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors
PT3322706T (pt) 2015-07-16 2021-03-08 Array Biopharma Inc Compostos de pirazolo[1,5-a]piridina substituídos como inibidores da quinase do ret
US10829484B2 (en) 2015-07-28 2020-11-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
EP3371171B1 (en) 2015-11-02 2023-10-25 Blueprint Medicines Corporation Inhibitors of ret
WO2017145050A1 (en) 2016-02-23 2017-08-31 Glaxosmithkline Intellectual Property Development Limited Pyridylpyridone derivative useful as a ret kinase inhibitor in the treatment of ibs and cancer
ES2904615T3 (es) 2016-03-16 2022-04-05 Plexxikon Inc Compuestos y métodos para la modulación de quinasas e indicaciones al respecto
WO2017161269A1 (en) 2016-03-17 2017-09-21 Blueprint Medicines Corporation Inhibitors of ret receptor tyrosine kinases
MX2018013885A (es) 2016-05-13 2019-08-16 Inst De Medicina Molecular Joaeo Lobo Antunes Métodos de tratamiento de enfermedades asociadas con células linfoides innatas del grupo 3 (cli3).
US10227329B2 (en) 2016-07-22 2019-03-12 Blueprint Medicines Corporation Compounds useful for treating disorders related to RET
JP2018052878A (ja) 2016-09-29 2018-04-05 第一三共株式会社 ピリジン化合物
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JP6888101B2 (ja) 2017-01-18 2021-06-16 アレイ バイオファーマ インコーポレイテッド RETキナーゼ阻害剤としての置換ピラゾロ[1,5−a]ピラジン化合物
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
JP2020519672A (ja) 2017-05-15 2020-07-02 ブループリント メディシンズ コーポレイション RET阻害剤とmTORC1阻害剤との組合せ及び異常なRET活性によって媒介されるがんを処置するためのその使用
US10093648B1 (en) * 2017-09-22 2018-10-09 Celgene Corporation Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof
TWI876442B (zh) * 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
WO2019143977A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
WO2019143991A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS
JP6997876B2 (ja) 2018-01-18 2022-02-04 アレイ バイオファーマ インコーポレイテッド Retキナーゼ阻害剤としての置換ピラゾリル[4,3-c]ピリジン化合物
BR112020020273A2 (pt) 2018-04-03 2021-04-06 Blueprint Medicines Corporation Inibidor de ret para uso no tratamento de câncer tendo uma alteração de ret
CN109096264B (zh) * 2018-08-28 2019-08-23 山东理工职业学院 Ret抑制剂及其制备方法、组合物和用途
CA3111984A1 (en) 2018-09-10 2020-03-19 Array Biopharma Inc. Fused heterocyclic compounds as ret kinase inhibitors
AU2020257301B2 (en) 2019-04-18 2025-10-23 The Johns Hopkins University Substituted 2-amino-pyrazolyl-(1,2,4)triazolo(1,5a) pyridine derivatives and use thereof
CN117903123A (zh) * 2020-02-20 2024-04-19 广州白云山医药集团股份有限公司白云山制药总厂 喹啉类化合物
TWI777509B (zh) * 2020-04-27 2022-09-11 美商美國禮來大藥廠 用於抑制ret激酶之化合物
EP4157829A1 (en) 2020-05-29 2023-04-05 Blueprint Medicines Corporation Solid forms of pralsetinib
TWI786742B (zh) * 2020-07-23 2022-12-11 大陸商深圳晶泰科技有限公司 吡啶酮類化合物及其製備方法和應用
ES3032873T3 (en) * 2020-11-06 2025-07-28 Lilly Co Eli Pyrazole derivatives as ret kinase inhibitors
JP2024522938A (ja) 2021-06-03 2024-06-21 フンダサン デー.アンナ ジ ソーメル チャンパリマウド エー ドクトル カルロス モンテス チャンパリマウド 脳-脂肪回路を介してilc2および肥満度を制御する神経-間葉単位
CN115626880B (zh) * 2022-11-15 2023-11-14 常州大学 3-硝基-5-氰基三氟甲苯的合成方法
CN116925023B (zh) * 2023-07-18 2025-11-21 江苏桐孚高新材料有限公司 2-全氟烷基-4h-吡喃-4-酮衍生物的改进合成方法
EP4650002A1 (en) * 2024-05-15 2025-11-19 Ludwig-Maximilians-Universität Aniline-based modulators of the nuclear receptor tlx (nr2e1)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20053476B (en) 1999-08-12 2005-03-25 Upjohn Co 3(5)-Amino-Pyrazole Derivatives, Process for Their Preparation and Their Use as Antitumor Agents
US20040019046A1 (en) * 2000-11-27 2004-01-29 Paolo Pevarello Phenylacetamido-pyrazole derivatives and their use as antitumor agents
DE10201764A1 (de) 2002-01-18 2003-07-31 Bayer Cropscience Ag Substituierte 4-Aminopyridin-Derivate
US7968574B2 (en) 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
MX2009003985A (es) * 2006-10-16 2009-04-27 Novartis Ag Fenil-acetamidas utiles como inhibidores de cinasa de proteina.
EP2099774A4 (en) * 2006-11-15 2010-11-24 Ym Biosciences Australia Pty L INHIBITORS OF KINASEACTIVITY
BR112012003661A2 (pt) * 2009-08-19 2017-04-25 Ambit Biosciences Corp "compostos de biarila e métodos de uso dos mesmos."
EP2651930B1 (en) 2010-12-16 2015-10-28 Boehringer Ingelheim International GmbH Biarylamide inhibitors of leukotriene production
AR095308A1 (es) 2013-03-15 2015-10-07 Glaxosmithkline Ip Dev Ltd Compuesto de 2-piridona, composición farmacéutica que lo comprende y su uso para preparar un medicamento

Also Published As

Publication number Publication date
CR20150490A (es) 2015-11-20
ES2616655T3 (es) 2017-06-13
AU2014229233B2 (en) 2016-08-11
IL241161A0 (en) 2015-11-30
ME02664B (me) 2017-06-20
EP2970191A1 (en) 2016-01-20
SMT201700152T1 (it) 2017-05-08
PE20151538A1 (es) 2015-11-18
HRP20170363T1 (hr) 2017-04-21
CL2015002514A1 (es) 2016-02-05
MX2015012286A (es) 2016-05-31
US20160002215A1 (en) 2016-01-07
RS55710B1 (sr) 2017-07-31
UY35465A (es) 2014-10-31
EP2970191B1 (en) 2016-12-21
JP2016516026A (ja) 2016-06-02
PH12015502044A1 (en) 2016-01-18
US9382238B2 (en) 2016-07-05
US20160271123A1 (en) 2016-09-22
LT2970191T (lt) 2017-03-10
BR112015023618A2 (pt) 2017-07-18
NZ628388A (en) 2016-09-30
EA201591738A1 (ru) 2016-01-29
CA2905627A1 (en) 2014-09-18
DK2970191T3 (en) 2017-03-20
EA029296B1 (ru) 2018-03-30
US9789100B2 (en) 2017-10-17
WO2014141187A1 (en) 2014-09-18
UA115264C2 (uk) 2017-10-10
HUE033423T2 (en) 2017-11-28
TW201524958A (zh) 2015-07-01
AU2014229233A1 (en) 2015-09-24
SI2970191T1 (sl) 2017-04-26
DOP2015000244A (es) 2015-12-31
SG11201506695UA (en) 2015-09-29
CN105051027A (zh) 2015-11-11
CY1118730T1 (el) 2017-07-12
PT2970191T (pt) 2017-03-23

Similar Documents

Publication Publication Date Title
PL2970191T3 (pl) Pochodne pirydyny jako inhibitory kinazy przebudowanej podczas transfekcji (RET)
DK3019496T3 (da) Pyrimidinderivater som kinaseinhibitorer
DK3319956T3 (da) Substituerede oxopyridinderivater
LT3342771T (lt) Heterocikliniai amidai kaip kinazės inhibitoriai
DK3527263T3 (da) Bipyrazolderivater som jak-inhibitorer
DK3371190T3 (da) Heterocykliske forbindelser som pi3k-gamma-inhibitorer
BR112018002709A2 (pt) derivados heterobicíclicos microbicidas
HUE049794T2 (hu) Új aminopirimidin származékok
BR112017020349A2 (pt) derivados heterobicíclicos microbicidas
DK3539961T3 (da) Polycykliske amidderivativer som cdk9-inhibitorer
BR112017007510A2 (pt) derivados heterocíclicos tetracíclicos com substituintes contendo enxofre ativos em termos pesticidas
DK3204378T3 (da) N-pyridinylacetamidderivater som hæmmere af wnt-signaleringsbanen
IL246054B (en) Tropomyosin-related kinase (trk) inhibitors
LT3371168T (lt) Indolin-2-ono dariniai
PL2945641T3 (pl) Cykloalkinowe pochodne sacharydów
IL249674A0 (en) Quinolizinone derivatives as pi3k inhibitors
DK3066089T3 (da) Substituerede n-acetyl-l-cysteinderivater og relaterede forbindelser
HUE036925T2 (hu) C-fms kináz inhibitorként használható helyettesített piridin származékok
EP3868751C0 (en) 2-AMINOQUINAZOLINE DERIVATIVES AS P70S6 KINASE INHIBITORS
DK3372589T3 (da) Pyrimidinderivat
DK3233862T3 (da) Imidazopyridazinderivater som pi3k-beta-inhibitorer
HUE046518T2 (hu) Cikloalkilcsoporthoz kapcsolt diheterociklusos származékok
BR112018002710A2 (pt) derivados heterobicíclicos microbicidas
TH1501005474A (th) อนุพันธ์ไพริดีนในรูปสารยับยั้งไคเนสถูกจัดเรียงใหม่ในระหว่างการทรานส์เฟคชั่น (ret)
TH1501006974A (th) อนุพันธ์เฮเทอโรไซคลิค